Quick10K

⚲

Endonovo Therapeutics

Filings

10-Q	2020-06-30	Filed 2020-08-19
S-1	2020-06-23	Public Filing
10-Q	2020-03-31	Filed 2020-06-12
10-K	2019-12-31	Filed 2020-05-04
10-Q	2019-09-30	Filed 2019-11-19
10-Q	2019-06-30	Filed 2019-08-13
10-Q	2019-03-31	Filed 2019-05-09
S-1	2019-01-07	Public Filing
10-K	2018-12-31	Filed 2019-04-15
10-Q	2018-09-30	Filed 2018-11-13
10-Q	2018-06-30	Filed 2018-08-13
10-Q	2018-03-31	Filed 2018-05-18
10-K	2017-12-31	Filed 2018-04-06
10-Q	2017-09-30	Filed 2017-11-07
10-Q	2017-06-30	Filed 2017-08-10
10-Q	2017-03-31	Filed 2017-05-12
10-K	2016-12-31	Filed 2017-04-17
10-Q	2016-09-30	Filed 2016-11-14
10-Q	2016-06-30	Filed 2016-08-12
10-Q	2016-03-31	Filed 2016-05-20
10-K	2015-12-31	Filed 2016-04-05
10-Q	2015-09-30	Filed 2015-11-23
10-Q	2015-06-30	Filed 2015-08-19
10-Q	2015-03-31	Filed 2015-05-19
10-K	2014-12-31	Filed 2015-04-03
10-Q	2014-09-30	Filed 2014-11-14
10-Q	2014-06-30	Filed 2014-08-19
10-Q	2014-03-31	Filed 2014-05-15
10-K	2013-12-31	Filed 2014-04-15
10-Q	2013-09-30	Filed 2013-12-18
10-Q	2013-06-30	Filed 2013-08-19
10-Q	2013-03-31	Filed 2013-05-20
10-K	2012-12-31	Filed 2013-04-16
10-K	2012-12-31	Filed 2013-04-16
10-Q	2012-09-30	Filed 2012-11-29
10-Q	2012-06-30	Filed 2012-08-20
10-Q	2012-03-31	Filed 2012-05-21
10-K	2011-12-31	Filed 2012-04-13

Reports

8-K	2020-08-06	Officers, Exhibits
8-K	2020-05-20
8-K	2020-05-19
8-K	2020-04-10
8-K	2020-03-02
8-K	2020-01-29
8-K	2019-12-11
8-K	2019-06-10
8-K	2019-01-01
8-K	2018-12-06
8-K	2018-09-18
8-K	2018-08-12

Endonovo Therapeutics Financials

ENDV Metrics, Comps, Filings

Quarterly | Annual

Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Equity

Income Statement ($MM Quarterly)

Revenue, G Profit, Net Income

Cash Flow ($MM Quarterly)

Ops, Inv, Fin


Comps ($'000 TTM)	Market Cap	Gross Margin	EV/EBITDA	Ret on Assets	Assets	Liabilities	Revenue	G Profit	Net Income	EBITDA	EV
US Stem Cell (USRM)	0	58%	-0.2	-481%	656	9,770	2,763	1,598	-3,158	-2,256	378
Bravatek Solutions (BVTK)	0	73%	0.0	-158%	151	8,437	199	146	-239	-114	-2
Visium Technologies (VISM)	0		0.0	-31,116%	3	3,141	0	0	-796	-796	-3
Fiverr (FVRR)
Zenergy Brands (ZNGY)	0	17%	0.0	-171%	2,124	8,074	2,085	345	-3,635	-3,635	-6
Patriot Scientific (PTSC)	0		1.2	-41%	1,925	228	0	0	-798	-797	-986
Granite Real Estate (GRP)
Growlife (PHOT)	0	33%	0.0	-130%	4,626	9,064	6,744	2,193	-6,029	-4,695	-201
Dais Analytic (DLYT)	0	36%	0.0	-597%	414	8,700	1,055	378	-2,470	-2,184	-14
Jumia (JMIA)
Rich Pharmaceuticals (RCHA)	0	-6%	0.0	-4,521%	37	6,396	115	-7	-1,692	-2,356	-6
InMode (INMD)
View Systems (VSYM)	0	100%	-0.8	-1,148%	27	1,083	1	1	-308	-272	226
Owl Rock Capital (ORCC)
Endonovo Therapeutics (ENDV)	0	73%	-0.8	-301%	3,414	19,980	204	150	-10,268	-9,617	7,448
Link Motion (LKM)	0			0%	853,628	377,864	0	0	0	0	-91,397
Cerence (CRNC)
W&E Source (WESC)	0	100%	0.0	-419%	14	182	1	1	-60	-60	-3
Ford Motor Credit (FMCC)	0	0%	15.7	1%	160,883,000	146,728,000	12,691,000	0	2,313,000	7,242,000	114,027,000
Sirva (SRVA)


Balance Sheet ($'000)	2011-06-30	2011-12-31	2012-03-31	2012-06-30	2012-09-30	2013-09-30	2015-06-30	2015-09-30	2015-12-31	2016-06-30	2016-09-30	2016-12-31	2017-03-31	2017-06-30	2017-09-30	2017-12-31	2018-03-31	2018-06-30	2018-09-30	2018-12-31	2019-03-31	2019-06-30	2019-09-30
Cash	111	70	52	11	3	1	18	27	41	79	95	56	113	24	64	90	95	68	665	379	58	548	5
Accounts Receivable		1	1	1	2												7	10	3	3	10	8	11
Inventory
PP&E	5	5	2	2	1	51	74	74	78	78	78	78	78	78	78	78	87	87	87	87	87	89	90
Assets	114	73	1,027	988	969	64	54	62	76	102	264	319	358	203	160	4,612	4,471	4,284	4,711	4,242	3,766	4,123	3,414
Accounts Payable	0	1																		157	199	281	346
Long-Term Debt						43	35	32	29	2,285	1,878	3,194	2,800	3,295	3,640	7,356	7,301	7,489	8,413	8,158	7,480	7,520	7,453
Liabilities	0	1	1,746	2,104	2,395	3,527	5,451	5,991	7,665	7,353	8,783	8,881	13,425	9,357	13,344	14,163	13,094	13,400	18,793	15,634	15,391	20,369	19,980
Stockholders' Equity	114	72	-719	-1,116	-1,426	-3,463	-5,398	-5,929	-7,589	-7,250	-8,519	-8,562	-13,066	-9,154	-13,184	-9,550	-8,623	-9,116	-14,082	-11,392	-11,625	-16,247	-16,566


Income Statement ($'000)	2011-06-30	2011-12-31	2012-03-31	2012-06-30	2012-09-30	2013-09-30	2015-06-30	2015-09-30	2015-12-31	2016-06-30	2016-09-30	2016-12-31	2017-03-31	2017-06-30	2017-09-30	2017-12-31	2018-03-31	2018-06-30	2018-09-30	2018-12-31	2019-03-31	2019-06-30	2019-09-30
Revenue	9		2	8	7	0	2	-0	0	0	0	0					7	13	21	42	45	63	54
Cost of Revenue							1	0	0	0	0	0						1	4	8	8	30	9
Gross Profit							1	-0	0	0	0	0						12	17	34	37	33	45
R&D																	114	44	5	111	63	48	35
SG&A
Tax	0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Income	21		-431	-431	-393	-452	-558	-1,281	-2,840	-1,454	-2,219	-740	-7,765	1,858	-6,672	1,769	-619	4,802	-5,948	1,382	-2,406	-7,838	-1,406


Cash Flow ($'000)	2011-06-30	2011-12-31	2012-03-31	2012-06-30	2012-09-30	2013-09-30	2015-06-30	2015-09-30	2015-12-31	2016-06-30	2016-09-30	2016-12-31	2017-03-31	2017-06-30	2017-09-30	2017-12-31	2018-03-31	2018-06-30	2018-09-30	2018-12-31	2019-03-31	2019-06-30	2019-09-30
Cash Operating			-20	-176	-33			-429	-211		-776	-659	-434	-914	-829	-813	-591	-742		-716	-528	-688	-1,017
Cash Investing			53	0	0						0	0	0	0	0	-3,000	-9	0		0	0	-2	-1
Cash Financing			10	135	25			438	229		792	620	492	825	882	3,826	605	714		430	208	1,179	475